T1916 Differentiation, Origin and Mesothelial Adhesive Potential Affect Growth and Metastasis of Ductal Adenocarcinoma of the Pancreas

2008 ◽  
Vol 134 (4) ◽  
pp. A-895
Author(s):  
Soeren Torge Mees ◽  
Christina Schleicher ◽  
Mario Colombo-Benkmann ◽  
Norbert Senninger ◽  
Joerg Haier
Keyword(s):  
Ductal Adenocarcinoma ◽  
Adenocarcinoma Of The Pancreas

scholarly journals CT Simplified Radiomic Approach to Assess the Metastatic Ductal Adenocarcinoma of the Pancreas

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1843
Author(s):  
Mirko D’Onofrio ◽  
Riccardo De Robertis ◽  
Gregorio Aluffi ◽  
Camilla Cadore ◽  
Alessandro Beleù ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Newly Diagnosed ◽  
Inclusion Criteria ◽  
Permeability Index ◽  
Metastatic Tumors ◽  
Qualitative And Quantitative ◽  
Portal Phase ◽  
Phase Images ◽  
Adenocarcinoma Of The Pancreas

The aim of this study was to perform a simplified radiomic analysis of pancreatic ductal adenocarcinoma based on qualitative and quantitative tumor features and to compare the results between metastatic and non-metastatic patients. A search of our radiological, surgical, and pathological databases identified 1218 patients with a newly diagnosed pancreatic ductal adenocarcinoma who were referred to our Institution between January 2014 and December 2018. Computed Tomography (CT) examinations were reviewed analyzing qualitative and quantitative features. Two hundred eighty-eight patients fulfilled the inclusion criteria and were included in this study. Overall, metastases were present at diagnosis in 86/288 patients, while no metastases were identified in 202/288 patients. Ill-defined margins and a hypodense appearance on portal-phase images were significantly more common among patients with metastases compared to non-metastatic patients (p < 0.05). Metastatic tumors showed a significantly larger size and significantly lower arterial index, perfusion index, and permeability index compared to non-metastatic tumors (p < 0.05). In the management of pancreatic ductal adenocarcinoma, early detection and correct staging are key elements. The study of computerized tomography characteristics of pancreatic ductal adenocarcinoma showed substantial differences, both qualitative and quantitative, between metastatic and non-metastatic disease.

Gastric- and intestinal-type marker expression in invasive ductal adenocarcinoma of the pancreas

2012 ◽  
Vol 11 (4) ◽  
pp. 424-428 ◽  
Author(s):  
Yuichi Takano ◽  
Nobuyuki Ohike ◽  
Takuma Tajiri ◽  
Kunio Asonuma ◽  
Kenji Harada ◽  
...  
Keyword(s):  
Intestinal Type ◽  
Ductal Adenocarcinoma ◽  
Invasive Ductal Adenocarcinoma ◽  
Marker Expression ◽  
Adenocarcinoma Of The Pancreas

scholarly journals The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas

2015 ◽  
Vol 112 (1) ◽  
pp. 80-85 ◽  
Author(s):  
Stephanie Downs-Canner ◽  
Mazen Zenati ◽  
Brian A. Boone ◽  
Patrick R. Varley ◽  
Jennifer Steve ◽  
...  
Keyword(s):  
Pulmonary Metastases ◽  
Ductal Adenocarcinoma ◽  
Adenocarcinoma Of The Pancreas

scholarly journals Paraneoplastic Opsoclonus Myoclonus in a Patient with Pancreatic Adenocarcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-3
Author(s):  
Divine C. Nwafor ◽  
Ashley B. Petrone ◽  
Joseph M. Collins ◽  
Amelia K. Adcock
Keyword(s):  
Saccadic Eye Movements ◽  
Small Cell ◽  
Ductal Adenocarcinoma ◽  
Small Cell Lung ◽  
The Third ◽  
Pancreatic Malignancy ◽  
Underlying Malignancy ◽  
Published Report ◽  
Opsoclonus Myoclonus Syndrome ◽  
Adenocarcinoma Of The Pancreas

Opsoclonus myoclonus syndrome (OMS) is an extremely rare neurological syndrome typically affecting as few as 1 in 10,000,000 people annually. OMS is characterized by the presence of involuntary, saccadic eye movements, as well as ataxia, including gait incoordination, rigidity, and tremor. The origin of OMS is unclear, but a significant percentage of OMS cases are indicative of an underlying malignancy, most commonly neuroblastoma and small cell lung cancer. Here we describe an adult patient with OMS, who was ultimately diagnosed with a small ductal adenocarcinoma of the pancreas. To our knowledge, this is the third published report of an association between OMS and pancreatic malignancy, and the only case where the pancreatic malignancy was detected prior to metastasis or autopsy at death. This case report highlights the importance of careful, aggressive malignancy screening with OMS, as the pancreatic duct cut-off sign may be overlooked if pancreatic malignancy is not suspected.

scholarly journals Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas

1998 ◽  
Vol 77 (1) ◽  
pp. 147-152 ◽  
Author(s):  
H Suwa ◽  
G Ohshio ◽  
T Imamura ◽  
G Watanabe ◽  
S Arii ◽  
...  
Keyword(s):  
Ductal Adenocarcinoma ◽  
Adenocarcinoma Of The Pancreas

Major arterial resection for stage 3 adenocarcinoma of the pancreas.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 362-362
Author(s):  
Benjamin Loveday ◽  
Koji Tomiyama ◽  
Nathan Zilbert ◽  
Amélie Tremblay St-Germain ◽  
Pablo Emilio Serrano Aybar ◽  
...  
Keyword(s):  
Overall Survival ◽  
Treatment Program ◽  
Oncologic Outcomes ◽  
Ductal Adenocarcinoma ◽  
R0 Resection ◽  
Negative Resection Margin ◽  
Surgical Exploration ◽  
Intention To Treat ◽  
Pancreas Resection ◽  
Adenocarcinoma Of The Pancreas

362 Background: Stage 3 pancreas ductal adenocarcinoma (PDAC) is defined by arterial involvement, and its resection remains controversial. The objective of this study was to evaluate clinical and oncologic outcomes for patients with stage 3 PDAC who entered a treatment program of neoadjuvant therapy (NAT) and pancreatic resection, with comparison between those who underwent arterial (AR) vs. standard resection (SR). Methods: This cohort study included patients from 2009-2016 in a single academic institution, with biopsy-proven potentially resectable stage 3 PDAC who entered a treatment program of NAT followed by surgical exploration if non-progressive disease on imaging. AR was performed if required to achieve R0 resection. Oncological outcomes were analyzed as intention to treat from diagnosis date. Results: Eighty-nine patients met inclusion criteria, of whom 87 (97.8%) received chemotherapy and 50 (56.2%) received radiotherapy. 46/89 (51.7%) underwent surgical exploration; 31 underwent pancreas resection (AR n = 20, SR n = 11), and 15 were found to have metastatic or unresectable disease. The AR group had a longer operative time (681 vs. 563 minutes, p = 0.0059) and more blood loss (1600 vs. 575 mL, p = 0.0004) compared with SR, with no difference between groups for blood transfusion, overall complications, pancreatic fistula, length of stay, reoperation, readmission or mortality. R0 rate was 100% for resected patients. Post-operative 90-day mortality was 1.1%. Median overall survival of resected patients was longer than in non-resected patients (25.9 vs. 14.8 months, p = 0.01), while AR had comparable overall survival to SR (19.7 vs. 28.4 months, p = 0.41). Conclusions: Patients with non-progressive stage 3 PDAC after NAT should be considered for pancreas resection. AR had comparable clinical and oncologic outcomes to SR. Resection may offer a survival advantage over non-surgical therapy alone, and AR should be considered if required to obtain a negative resection margin.

Sign in / Sign up

Export Citation Format

Share Document